Clinical Trial

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Protocol Amendment History 6 changes
notable Trial sites expanded: 391 -> 394 locations 2026-07-24
notable Trial sites expanded: 383 -> 391 locations 2026-07-08
notable Trial sites expanded: 363 -> 383 locations 2026-06-17
notable Trial sites expanded: 357 -> 363 locations 2026-05-28
notable Trial sites expanded: 351 -> 357 locations 2026-05-08
notable Trial sites expanded: 341 -> 350 locations 2026-04-03
Trial Details
NCT Number NCT07116967
Lead Sponsor Bristol-Myers Squibb
Conditions Plaque Psoriasis
Enrollment 3,040 participants
Start Date 2025-09-22
Primary Completion 2031-01-16 (estimated)
Study Completion 2031-01-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-23